These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22189833)

  • 41. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
    Misof BM; Roschger P; Baldini T; Raggio CL; Zraick V; Root L; Boskey AL; Klaushofer K; Fratzl P; Camacho NP
    Bone; 2005 Jan; 36(1):150-8. PubMed ID: 15664013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone.
    Peter CP; Guy J; Shea M; Bagdon W; Kline WF; Hayes WC
    J Pharmacol Exp Ther; 1996 Jan; 276(1):271-6. PubMed ID: 8558442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects.
    Tjhia CK; Odvina CV; Rao DS; Stover SM; Wang X; Fyhrie DP
    Bone; 2011 Dec; 49(6):1279-89. PubMed ID: 21958843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.
    Gourion-Arsiquaud S; Allen MR; Burr DB; Vashishth D; Tang SY; Boskey AL
    Bone; 2010 Mar; 46(3):666-72. PubMed ID: 19925895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The antifracture efficacy of alendronate.
    Seeman E
    Int J Clin Pract Suppl; 1999 Apr; 101():40-5. PubMed ID: 12675021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The bone architecture is enhanced with combined PTH and alendronate treatment compared to monotherapy while maintaining the state of surface mineralization in the OVX rat.
    Campbell GM; Bernhardt R; Scharnweber D; Boyd SK
    Bone; 2011 Aug; 49(2):225-32. PubMed ID: 21515436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Material and nanomechanical properties of bone structural units of cortical and trabecular iliac bone tissues from untreated postmenopausal osteoporotic women.
    Farlay D; Falgayrac G; Ponçon C; Rizzo S; Cortet B; Chapurlat R; Penel G; Badoud I; Ammann P; Boivin G
    Bone Rep; 2022 Dec; 17():101623. PubMed ID: 36213624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
    Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
    Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women.
    Boivin G; Vedi S; Purdie DW; Compston JE; Meunier PJ
    Bone; 2005 Mar; 36(3):562-7. PubMed ID: 15777681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
    J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
    Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF
    J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
    Borah B; Dufresne TE; Ritman EL; Jorgensen SM; Liu S; Chmielewski PA; Phipps RJ; Zhou X; Sibonga JD; Turner RT
    Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate.
    Bajaj D; Geissler JR; Allen MR; Burr DB; Fritton JC
    Bone; 2014 Jul; 64():57-64. PubMed ID: 24704262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of vitamin K2 (menatetrenone) and alendronate on bone mineral density and bone strength in rats fed a low-magnesium diet.
    Kobayashi M; Hara K; Akiyama Y
    Bone; 2004 Nov; 35(5):1136-43. PubMed ID: 15542039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
    Cheng Z; Yao W; Zimmermann EA; Busse C; Ritchie RO; Lane NE
    J Bone Miner Res; 2009 Feb; 24(2):209-20. PubMed ID: 18847326
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparable effects of alendronate and strontium ranelate on femur in ovariectomized rats.
    Chen B; Li Y; Yang X; Xie D
    Calcif Tissue Int; 2013 Nov; 93(5):481-6. PubMed ID: 23897224
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Ward LM; Rauch F; Whyte MP; D'Astous J; Gates PE; Grogan D; Lester EL; McCall RE; Pressly TA; Sanders JO; Smith PA; Steiner RD; Sullivan E; Tyerman G; Smith-Wright DL; Verbruggen N; Heyden N; Lombardi A; Glorieux FH
    J Clin Endocrinol Metab; 2011 Feb; 96(2):355-64. PubMed ID: 21106710
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys.
    Yamagami Y; Mashiba T; Iwata K; Tanaka M; Nozaki K; Yamamoto T
    Bone; 2013 May; 54(1):1-7. PubMed ID: 23356990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.